Cullinan Therapeutics to present new results from REZILIENT1 trial

Cullinan Therapeutics (CGEM), Taiho Pharmaceutical and Taiho Oncology announced new results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations who have received prior therapy. These data will be presented on Sunday, June 1 at the American Society of Clinical Oncology annual meeting as an oral presentation. As of the December 2024 data cutoff, 244 patients were enrolled in REZILIENT1 and received at least one dose of 100 mg zipalertinib. The overall efficacy population consisted of all patients who received at least one dose of 100 mg zipalertinib and had approximately 8 months of minimum follow-up at data cutoff. Patients had received a median of 2 prior therapies, and 39% of patients had a history of brain metastases. With median follow-up of 9.3 months, zipalertinib demonstrated: In the overall efficacy population, confirmed overall objective response rate was 35% with median duration of response of 8.8 months; in patients with prior platinum-based chemotherapy only, ORR was 40% with mDOR of 8.8 months, consistent with REZILIENT1 Phase 1/2a results; in patients with prior chemo and amivantamab, ORR was 30% with mDOR of 14.7 months; in patients with prior chemo and amivantamab, ORR was 24% with mDOR of 8.5 months and in patients with brain metastases, the ORR was 31% with mDOR of 8.3 months. The safety analysis population included all REZILIENT1 patients who received at least one dose of 100 mg zipalertinib. The results showed that zipalertinib demonstrated a manageable safety profile in this heavily pre-treated patient population, consistent with previously reported data. The most common treatment-related adverse events were paronychia, rash, dermatitis acneiform, dry skin, diarrhea and stomatitis. The majority of TRAEs were grade 1 or 2. The most common grade 3 TRAEs were anemia, pneumonitis and rash, increased alanine aminotransferase, diarrhea, and decreased platelet count.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

2 days ago

• Yahoo

Draig secures $140m for neuropsychiatric disorder therapies

Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to advance its portfolio of next-generation therapies to treat major neuropsychiatric disorders. The investment was led by Access Biotechnology and saw contributions from Canaan Partners, SR One, Schroders Capital and Sanofi Ventures. The round also included SV Health Investors as seed investors and intermediate capital group. The investment will be used to advance the company's lead candidate, DT-101, into Phase II trials for major depressive disorder (MDD). DT-101 was developed to facilitate alpha-amino-3-hydroxy-5-methyl-4-isooxazole-propionic acid (AMPA) receptor modulation while ensuring that safety is not compromised. This was evidenced by data from a Phase Ia programme involving more than 60 subjects, which showed target engagement through the magnetoencephalography technique. Draig was established through a partnership between Cardiff University's Medicines Discovery Institute and SV Health Investors. Access Biotechnology head Liam Ratcliffe stated: 'Despite numerous treatments available for neuropsychiatric disorders, a significant unmet need remains with many patients continuing to experience inadequate symptom relief and high rates of relapse. 'Draig's differentiated approach, which targets core mechanisms underlying these complex conditions, has the potential to deliver a real breakthrough for patients.' As well as advancing DT-101, the new capital injection will also support the progression of two gamma-aminobutyric acid type A (GABAA) receptor modulators towards clinical trials in 2026. These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options. Draig co-founder and executive chair and SV Health Investors operating partner Ruth McKernan stated: 'Making the best molecules to rebalance brain networks has been John and Simon's life work. It has been a professional highlight for me to be part of creating this hugely promising company too.' "Draig secures $140m for neuropsychiatric disorder therapies" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Yahoo

12-06-2025

• Yahoo

Chatham Public Health Department shares tips to prevent tick bites

PITTSBORO — Chatham County residents are not the only ones outside enjoying the warmer weather. According to the Chatham County Public Health Department, higher temperatures during summer increase the number of uninvited guests: ticks. 'Even though tick bites can occur year-round, ticks are most active during the warmer months,' Chatham County Public Health Department Environmental Health Director Anne Lowry said. 'Because they feed off blood from both people and animals, ticks can make you sick by spreading a disease from one host to the next.' In 2024, around 10% of Chatham County residents reported that they had been diagnosed with a Tick-Borne Illness — nearly double the percentage who reported one in 2021. Although many TBIs circulate in Chatham County, two are most common: Ehrlichiosis• Spread by the lone star tick • Symptoms: Fever, chills, headache, muscle aches, upset stomach • Spotted Fever Group Rickettsiosis • Spread by the American dog tick • Symptoms: Dark scab near bite, fever, headache, rash In 2023, Chatham County had the highest reported Ehrlichiosis and Spotted Fever Group Rickettsiosis incidence rates per 100,000 population of any county in North Carolina. According to Lowry, some tick bites can also cause allergies such as Alpha-Gal syndrome, which makes an infected individual allergic to mammal meat. This summer, the Chatham County Public Health Department recommends these steps to fight tick bites: Prepare for wooded or grassy areas When walking in the woods or tall grass, wear long sleeves and pants, tuck pants into socks, and use tick repellents. Treat your clothes with products containing 0.5% permethrin. Check for ticks after going outside Look over your entire body, especially in hard-to-see places like behind your knees, underarms, around your waist, and in your hair. Remove an attached tick as soon as possible Use tweezers to grab the tick as close to the skin's surface as possible. Gently pull straight up until all parts of the tick are removed. Keep an eye on any tick bites After removing the tick, monitor the bite. Watch for signs of a rash, swelling, or flu-like symptoms. If you experience these symptoms, see your health care provider and let them know a tick recently bit you. Kits are also available to help remove ticks at the CCPHD's Pittsboro office. 'Don't let ticks tag along on your summer adventures,' Lowry said. 'By following these precautions, you can enjoy the outdoors with peace of mind.' To learn more about how to prevent tick bites, visit To learn more about Alpha-Gal Syndrome visit

Yahoo

05-06-2025

• Yahoo

Australia unleashes twin AI supercomputers in push to lead medical, climate research

Australia's AI supercomputing ambitions are hitting top gear, with two major launches unveiled this week that aim to supercharge research in medicine, climate science, and Melbourne, La Trobe University has switched on the country's first AI supercomputer of its kind—a NVIDIA DGX H200 system—dedicated to transforming medical at NEXTDC's data centre in Tullamarine, the supercomputer is backed by $10 million from the Allan Labor for Economic Growth and Jobs Danny Pearson, who visited the site, said: 'Victoria is proud to be home to this supercomputer that will deliver more medical breakthroughs and improve healthcare for Victorians and people around the world.' The system will enable the Australian Centre for Artificial Intelligence in Medical Innovation (ACAMI) to analyse large volumes of health data and complex 3D imaging in hours, drastically reducing research time for projects such as clinical trials, precision oncology, immunotherapy, and cardiovascular risk prediction.'The potential of AI in medical and biotech research is huge,' said La Trobe Vice-Chancellor Professor Theo Farrell.'The DGX H200 enables faster translation of research into clinical trials and personalised therapies.'The supercomputer will also support innovations in digital pathology and cancer relapse-risk prediction, with early projects including a partnership with The Florey Institute on rare neurological diseases such as Niemann-Pick type C.'The super processing performance of NVIDIA DGX H200 systems will help us explore more options and get results faster,' said Dr Ya Hui Hung from The Monash University has announced its own major push into AI computing with MAVERIC—short for Monash AdVanced Environment for Research and Intelligent by a AU$60 million (US$39 million) investment, the system will be built over the next two years, with activation expected in 2026. According to the university, MAVERIC will 'fill a critical gap in Australia's high-performance computing infrastructure,' and position the institution as a 'leader in AI-driven research within the international higher education and research sector.'The platform will initially be used for early cancer detection, managing chronic diseases, empowering clinical trials, and accelerating drug discovery. It will also power climate change and planetary health research, analysing complex datasets related to air quality, Antarctic ecosystems, and the effects of heat on populations.'Investment in world-leading AI is a crucial step in supercharging our sovereign research capabilities,' said Monash Vice-Chancellor Sharon Pickering.'Monash is a well-established ecosystem of world-class researchers, health networks and partners with large-scale data and pre-identified massive research questions ready to be solved… Until now, the missing link has been the necessary compute infrastructure to fully maximise this opportunity,' she university said MAVERIC will be powered entirely by renewable energy, aligning with its net-zero targets. It also plans to use the platform for training students in ethical, human-centred AI development across undergraduate and postgraduate already operates high-performance systems like M3 and MonARCH, comprising thousands of CPU cores and multiple GPU nodes.